Skip to main content
HVIVO PLC logo

HVIVO PLC — Investor Relations & Filings

Ticker · HVO ISIN · GB00B9275X97 LEI · 213800VT5KBM7JLIV118 IL Professional, scientific and technical activities
Open in API
Filings indexed 758 across all filing types
Latest filing 2024-02-15 Remuneration Information
Country GB United Kingdom
Listing IL HVO

About HVIVO PLC

https://hvivo.com/

hVIVO plc is a full-service contract research organization (CRO) and a leading specialist in human challenge trials. The company provides end-to-end clinical development solutions for a global biopharma client base, focusing on infectious and respiratory diseases. Its services span from preclinical consultancy to Phase III clinical trials, including first-in-human studies, biometry, and consulting. hVIVO operates a state-of-the-art quarantine facility in London and provides advanced laboratory services under its hLAB brand. Through subsidiaries such as CRS and Venn Life Sciences, it offers early-phase clinical trial expertise and patient recruitment across multiple clinical sites. The company's integrated approach is designed to accelerate the development of vaccines and therapeutics.

Recent filings

Filing Released Lang Actions
Long Term Incentive Plan / PDMR Notification
Remuneration Information Classification · 100% confidence The document is an official announcement disseminated via RNS (RNS Number: 1878D) on February 15, 2024. The content explicitly details the granting of incentive options (LTIP Options) to the Chief Financial Officer (Stephen Pinkerton) and includes a formal table titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. This structure and content are characteristic of insider trading disclosures or director's dealing reports, specifically concerning executive compensation/share transactions. This aligns directly with the definition for Director's Dealing (DIRS). Although it involves an incentive plan, the core regulatory requirement being met is the disclosure of a transaction by a PDMR.
2024-02-15 English
Result of Secondary Placing
Director's Dealing Classification · 98% confidence The document is an official announcement from hVIVO PLC, dated 14 February 2024, titled "Result of Secondary Placing." It details the successful sale of a significant number of shares by existing shareholders (including the Chairman and a Non-Executive Director) via an accelerated bookbuild process. This involves changes in share ownership by directors and executives, which falls under insider dealing/director's dealing, but more specifically, it is a notification of a transaction involving the disposal of shares by persons discharging managerial responsibilities (PDMRs) and closely associated persons, as required by MAR (Market Abuse Regulation). While it involves director transactions (DIRS), the core subject is the capital transaction (share sale/placing) and the subsequent notification of PDMR transactions. Since the document explicitly details the sale of shares by directors/executives and their resulting holdings, it strongly aligns with the 'Director's Dealing' category (DIRS). It is also a form of capital change, but DIRS is more specific for executive transactions. Given the detailed MAR disclosure regarding transactions by persons discharging managerial responsibilities (Cathal Friel and Brendan Buckley), DIRS is the most appropriate classification.
2024-02-14 English
Proposed Secondary Placing of Ordinary Shares
Capital/Financing Update Classification · 98% confidence The document is an official announcement dated February 14, 2024, issued via RNS (RNS Number : 0412D). The content explicitly details a 'Proposed Secondary Placing of not less than 14 million Existing Ordinary Shares' being conducted via an 'accelerated bookbuild' involving directors/insiders (Selling Shareholders) selling shares to satisfy institutional demand. This transaction involves the issuance/sale of company shares by existing holders, which falls under the category of capital/financing activities, specifically related to share transactions. The most fitting category is 'Capital/Financing Update' (CAP) or 'Transaction in Own Shares' (POS). Since this is a secondary placing by existing shareholders (directors) to institutional investors, it is fundamentally a capital market transaction concerning the structure of share ownership, often announced via regulatory channels. Given the focus on the placement of shares and the involvement of placing agents (Cavendish and Peel Hunt), 'Capital/Financing Update' (CAP) is highly appropriate, as it covers fundraising and capital structure changes. However, 'Transaction in Own Shares' (POS) specifically covers the repurchase or issuance of shares. Since this is a secondary sale by insiders, it is a significant capital market event. Given the context of share placement and the regulatory nature (RNS), 'CAP' (Capital/Financing Update) is a strong fit, but 'POS' (Transaction in Own Shares) is also relevant if interpreted broadly as a change in share capital structure via transaction. Since the document describes a secondary placing by directors, which is a form of capital market activity to adjust share distribution, 'CAP' is chosen as the broader category for financing activities, although it is also a transaction in shares. Given the explicit mention of 'Placing' and the involvement of placing agents, this is a capital raising/restructuring event. I will classify it as CAP, as it is a major capital structure adjustment announcement.
2024-02-14 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 9027B' and contains the standard formatting and concluding remarks associated with RNS (Regulatory News Service) announcements from the London Stock Exchange. The content itself is a 'TR-1: Standard form for notification of major holdings,' which details changes in significant share ownership (crossing a threshold) by JPMorgan Asset Management Holdings Inc. This type of filing, reporting changes in major shareholdings, corresponds directly to the definition for Major Shareholding Notification (MRQ). Although it is an RNS announcement, MRQ is the more specific classification for the content type.
2024-02-02 English
Trading update
Earnings Release Classification · 100% confidence The document begins with an 'RNS Number' and explicitly states that the information is being disseminated via 'Regulatory Information Service ("RIS")'. The content provides an 'unaudited trading update for the year ended 31 December 2023', detailing key financial highlights (revenue, EBITDA, cash) and future guidance. This structure—a brief announcement of preliminary financial results for a period—is characteristic of an Earnings Release (ER). Although it is distributed via RNS, the primary content type is the financial update itself, not just a notice that a report is coming. Since it is an update on period results (Year Ended 31 Dec 2023), it is classified as an Earnings Release (ER) rather than a comprehensive Annual Report (10-K) or a general Regulatory Filing (RNS). The length (11,553 chars) is substantial enough to contain the core results, distinguishing it from a mere RPA. FY 2023
2024-01-30 English
Broker change
Board/Management Information Classification · 99% confidence The document is an official announcement released via RNS (RNS Number: 8647Y) on January 8, 2024. The primary content announces the appointment of a Nominated Adviser and Joint Broker (Cavendish Capital Markets Limited and Peel Hunt LLP). Additionally, it contains detailed disclosures regarding the current and past directorships of several directors (Elaine Sullivan, Brendan Buckley, Cathal Friel) pursuant to AIM Rule 17. This type of announcement, dealing with changes in senior personnel (management/board) and required regulatory disclosures related to those individuals, most closely aligns with the 'Board/Management Information' category (MANG). While it is distributed via RNS, the specific subject matter is management changes, making MANG a more precise fit than the general RNS fallback.
2024-01-08 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.